This study was conducted to obtain information on the tissue plasminogen activator inhibitor-1 (PAI-1) and fibrinogen level in chronic renal failure patients on regular haemodialysis in a trial to find out any changes that might contribute to thrombosis and bleeding.
This study was concluced on 40 chronic renal failure pations regular haemodialysis (HD) thrice weekly four hours each , with acetate based dialysate for about 1-13 years prior to the study.
The study group consisted of 20 men and 20 women, 27 to 73 years old. The heamodialysis prescription was 12 to 13.5 h / wk, with the use of 1.1 to 1.3m2 curophane hollow – fiber dialyser. The dialysers were not reused. In addition to 10 healthy volunteers with matched age and sex as acontrol group.
The main causes of chronic renal failure were hypertensive glomerulosclerosis and diabetic nephropathy disease in most of patients.
All patients were anuric and under treatment by heparin on the dialysis session ranging from 7500-15000 IU.
Heamodialysis (HD) was performed with volumetrically controlled machines.
In our work the assessment of plasma fibrinogen levels in the study group are significantly increase after haemodialysis in comparison to before haemodialysis (P≤ 0.001).
However plsma fibrinogen level showed non significant chang between study group and control group (P> 0.05).
In this study plasma plasminogen activator inhibitor-1 (PAI-1) levels revealed high significant decrease after haemodialysis in comparison to before haemodysis (P< 0.001).
Plasma plasminogen activator inhibitor-1 (PAI-1) levels revealed significant decrease before and after haemodialysis compared to controls (P<0.001).
In conclusion: coagulation and fibrinolysis are enhanced on regular haemodialysis treated (RDT) patients, a majority of patients on dialysis are in ahamostatic disturbance state, which need careful adjustment of an anticoagulant regimens, by the lowering of plasma level of tissue plasminogen thrombosis activator inhibitor-1 (PAI-1), there is tendency to bleeding rather than thrombosis in regular haemodialysis treatment patient